No Data
No Data
Teyi Pharmaceutical: Report for the first quarter of 2025
Teyi Pharmaceutical: 2024 Annual Report Summary
Teyi Pharmaceutical: 2024 Annual Report
Teyi Pharmaceutical Group (002728.SZ): In the first quarter, the net income was 31.5673 million yuan, a year-on-year increase of 244.82%.
On April 25, Gelonghui reported that Teyi Pharmaceutical Group (002728.SZ) announced its first quarter report for 2025, with revenue of 0.295 billion yuan, a year-on-year increase of 79.29%; net income attributable to shareholders of the listed company was 31.5673 million yuan, a year-on-year increase of 244.82%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 31.7069 million yuan, a year-on-year increase of 255.28%; basic EPS was 0.06 yuan.
Teyi Pharmaceutical Group (002728.SZ) has repurchased 2.48% of its shares at a cost of 93.9418 million yuan.
Teyi Pharmaceutical Group (002728.SZ) announced that as of February 28, 2025, it will conduct transactions via centralized competitive bidding...
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.